Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953472 · ClinicalTrials.gov registry record · Phase 1
B-type Natriuretic Peptide (BNP) in Human Hypertension
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00953472: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT00953472 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00953472, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The investigators working hypothesis is that human hypertension is in part due to a derangement in the endocrine function of the heart - a primary or secondary mechanism - resulting in a relative deficiency of the natriuretic peptides (NP). The remodeled hypertensive heart could result in altered processing and degradation of B-type NP resulting in altered molecular forms with decreased biological activity. The investigators further hypothesized the chronic administration of BNP in subjects with hypertension, is feasible, safe and will induce a sustained reduction in blood pressure.
Interventions
- DRUG brain natriuretic peptide
- OTHER no-added salt diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00953472
The ClinicalTrials.gov registry entry for NCT00953472 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which brain natriuretic peptide is the first listed.
NCT00953472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00953472 about?
NCT00953472 is a clinical study titled "B-type Natriuretic Peptide (BNP) in Human Hypertension". The investigators working hypothesis is that human hypertension is in part due to a derangement in the endocrine function of the heart - a primary or secondary mechanism - resulting in a relative deficiency of the natriuretic peptides (NP). The remodeled hypertensive heart could result in altered pr...
What is the current status of trial NCT00953472?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2009-02. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00953472?
The interventions under investigation include: brain natriuretic peptide (DRUG), no-added salt diet (OTHER).
Who is sponsoring clinical trial NCT00953472?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.